**Supplemental Table S1. Patient disposition**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Spartalizumab 400 mg Q4W (*N* = 82)** | **Chemotherapya (*N* = 40)** | **Crossover to Spartalizumab 400 mg Q4W (*N* = 25)** | **All Spartalizumab**  **(*N* = 107)** |
| **Patients randomized, *n* (%)** | | | | |
| Treatment ongoingb | 16 (19.5) | 3 (7.5) | 3 (12.0) | 19 (17.8) |
| End of treatment | 66 (80.5) | 37 (92.5) | 22 (88.0) | 88 (82.2) |
| **Reason for discontinuation, *n* (%)** | | | | |
| Progressive disease | 59 (72.0) | 32 (80.0) | 16 (64.0) | 75 (70.1) |
| Death | 4 (4.9) | 2 (5.0) | 2 (8.0) | 6 (5.6) |
| Physician decision | 1 (1.2) | 1 (2.5) | 2 (8.0) | 3 (2.8) |
| Patient/guardian decision | 1 (1.2) | 2 (5.0) | 1 (4.0) | 2 (1.9) |
| Adverse event | 1 (1.2) | 0 | 1 (4.0) | 2 (1.9) |
| Q4W, every 4 weeks.  aPer investigator's choice. bPatients ongoing at the time of the data cut-off date, October 11, 2018. | | | | |